| SC 13G/A | 2018-02-14 | Palo Alto Investors, LLC | Epizyme, Inc. | 6,860,843 | 9.9% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Epizyme, Inc. | 7,531,261 | 10.9% | EDGAR |
| SC 13G/A | 2018-02-09 | VANGUARD GROUP INC | Epizyme, Inc. | 4,245,683 | 6.1% | EDGAR |
| SC 13G | 2018-02-01 | BlackRock Inc. | Epizyme, Inc. | 3,965,391 | 5.7% | EDGAR |
| SC 13G/A | 2017-10-10 | BlackRock Inc. | Epizyme, Inc. | 3,385,729 | 5.0% | EDGAR |
| SC 13G/A | 2017-04-03 | Palo Alto Investors, LLC | Epizyme, Inc. | 4,699,675 | 8.1% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Epizyme, Inc. | 8,166,247 | 14.1% | EDGAR |
| SC 13G/A | 2017-02-09 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 6,543,327 | 11.3% | EDGAR |
| SC 13G | 2017-02-09 | VANGUARD GROUP INC | Epizyme, Inc. | 3,079,796 | 5.3% | EDGAR |
| SC 13G | 2017-01-30 | BlackRock Inc. | Epizyme, Inc. | 3,176,408 | 5.5% | EDGAR |
| SC 13G/A | 2017-01-12 | Palo Alto Investors, LLC | Epizyme, Inc. | 3,035,796 | 5.2% | EDGAR |
| SC 13G | 2016-02-16 | Palo Alto Investors, LLC | Epizyme, Inc. | 2,660,979 | 6.4% | EDGAR |
| SC 13G/A | 2016-02-12 | FMR LLC | Epizyme, Inc. | 6,181,700 | 14.8% | EDGAR |
| SC 13G/A | 2016-02-12 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 5,245,627 | 12.6% | EDGAR |
| SC 13G/A | 2016-02-10 | MPM BioVentures IV QP LP | Epizyme, Inc. | 1,398,493 | 3.4% | EDGAR |
| SC 13D/A | 2016-01-19 | NEW ENTERPRISE ASSOCIATES 13 LP | Epizyme, Inc. | 6,260,851 | 11.4% | EDGAR |
| SC 13G/A | 2015-02-17 | KLEINER PERKINS CAUFIELD & BYERS XIII, LLC | Epizyme, Inc. | 3,838,167 | 11.2% | EDGAR |
| SC 13G/A | 2015-02-13 | FMR LLC | Epizyme, Inc. | 4,391,746 | 12.9% | EDGAR |
| SC 13G/A | 2015-02-05 | MPM BioVentures IV QP LP | Epizyme, Inc. | 1,951,645 | 5.7% | EDGAR |
| SC 13G/A | 2015-01-06 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 4,114,008 | 12.0% | EDGAR |